Last update Jan. 15, 2022

Hydrosmin

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Flavonoid compound. Flavonoids are phenolic compounds naturally occurring that are abundantly present in all plants and in some seaweed.

They are ingested when drinking fruits, vegetables, tea and red wine, for example. (Serafini 1996)

Most important types are: anthocyanins, chalcons, flavonols, flavones, flavonoids and tannins. 

Attributed anti-oxidant activity and other properties that have not been fully shown yet (Martinez 2016, Morling 2015, Cohen 2012, AESAN 2012), as amelioration of capillary vessel function which is a reason to be used for treatment of venous insufficiency (varicose veins) and prevention of arteriosclerosis.

They appear naturally in the breast milk in amounts related to mother's diet. (Romaszko 2014, Song 2013)

No risk for toxic nor side-effects in humans have been found (AESAN 2012). No problems have been observed in infants whose mothers were treated with troxerutin. (Krajnovic 1977)

Some flavonoids such as diosmin and hydrosmin are classified as having low therapeutic utility. (GFD 2011)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Hydrosmin is also known as


Hydrosmin in other languages or writings:

  • C30H36O16 (Molecular formula)
  • C05CA05 (ATC Code/s)

Tradenames

Main tradenames from several countries containing Hydrosmin in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 653 daltons

References

  1. AEMPS. Hidrosmina. Ficha técnica. 2016 Full text (in our servers)
  2. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Abstract
  3. Morling JR, Yeoh SE, Kolbach DN. Rutosides for treatment of post-thrombotic syndrome. Cochrane Database Syst Rev. 2015 Abstract
  4. Romaszko E, Wiczkowski W, Romaszko J, Honke J, Piskula MK. Exposure of breastfed infants to quercetin after consumption of a single meal rich in quercetin by their mothers. Mol Nutr Food Res. 2014 Abstract
  5. Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest. 2012 Abstract
  6. AESAN. Informe del Comité Científico de la Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) sobre condiciones de uso de determinadas sustancias distintas de vitaminas, minerales y plantas para ser empleadas en complementos alimenticios - 1. Revista del comité científico nº 17. 2012 Full text (in our servers)
  7. DGF. Dirección General de Farmacia. Servicio Canario de la Salud. Listado de fármacos considerados de Utilidad terapéutica Baja (UTB). None 2011 Full text (in our servers)
  8. Serafini M, Ghiselli A, Ferro-Luzzi A. In vivo antioxidant effect of green and black tea in man. Eur J Clin Nutr. 1996 Abstract
  9. Krajnovic P. [The influence of the combination of coumarin and troxerutin on infantile blood parameter in lactation period. Short communication (author's transl)]. Arzneimittelforschung. 1977 Abstract

Total visits

12,256

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM